All 1 tracked stories fall under one category: funding. Of the tracked stories, 1 of 1 also mention Apyx Medical Corporation, the most common co-covered peer. Renuvion appears in 1 tracked Biotech story from August 13, 2026. The tracked stories average 2 original sources each.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Renuvion
All 1 tracked stories fall under one category: funding. Of the tracked stories, 1 of 1 also mention Apyx Medical Corporation, the most common co-covered peer. Renuvion appears in 1 tracked Biotech story from August 13, 2026. The tracked stories average 2 original sources each.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Renuvion. Shared-story counts are live from our verified record — not editorial picks.
For biotech and pharma investors, Apyx Medical's Q1 loss of $0.05 per share beat consensus by $0.06, but the stock fell 1.8% to $4.38 on low volume. Mixed analyst ratings and a $6.50 consensus target raise questions about whether the small-cap device maker can convert clinical and operational beats into stock appreciation. Institutional repositioning signals ongoing evaluation of the company's commercial ramp.
